HomeCompareBOID vs ABBV

BOID vs ABBV: Dividend Comparison 2026

BOID yields 5.58% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.7K in total portfolio value
10 years
BOID
BOID
● Live price
5.58%
Share price
$44.24
Annual div
$2.47
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$0.57
Full BOID calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BOID vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBOIDABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BOID + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BOID pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BOID
Annual income on $10K today (after 15% tax)
$474.57/yr
After 10yr DRIP, annual income (after tax)
$0.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BOID + ABBV for your $10,000?

BOID: 50%ABBV: 50%
100% ABBV50/50100% BOID
Portfolio after 10yr
$61.5K
Annual income
$12,386.17/yr
Blended yield
20.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BOID
No analyst data
Altman Z
0.3
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BOID buys
0
ABBV buys
0
No recent congressional trades found for BOID or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBOIDABBV
Forward yield5.58%3.06%
Annual dividend / share$2.47$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$20.6K$102.3K
Annual income after 10y$0.57$24,771.77
Total dividends collected$567.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BOID vs ABBV ($10,000, DRIP)

YearBOID PortfolioBOID Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,979$279.16$11,550$430.00$571.00ABBV
2$11,891$143.22$13,472$627.96$1.6KABBV
3$12,796$72.48$15,906$926.08$3.1KABBV
4$13,728$36.45$19,071$1,382.55$5.3KABBV
5$14,707$18.27$23,302$2,095.81$8.6KABBV
6$15,746$9.15$29,150$3,237.93$13.4KABBV
7$16,853$4.58$37,536$5,121.41$20.7KABBV
8$18,035$2.29$50,079$8,338.38$32.0KABBV
9$19,298$1.14$69,753$14,065.80$50.5KABBV
10$20,650$0.57$102,337$24,771.77$81.7KABBV

BOID vs ABBV: Complete Analysis 2026

BOIDStock

Bank of Idaho Holding Company operates as the holding company for Bank of Idaho that provides personal and business banking products and services in Idaho. The company offers checking and savings, and money market accounts, as well as individual retirement accounts, certificate of deposit, and various accounts and deposits; and auto, home, recreational vehicle, personal, agriculture, small business administration and FSA, commercial real estate, term operating capital, term equipment, and home equity loans, as well as lines of credit, letters of credit, and debit and credit cards. It also provides automated clearing house payments and debits, bill payments, remote and mobile deposits, sweep accounts, trusts, investment management and custody accounts, estate planning, annuities, 401(k), safe deposit boxes, digital wallet, teller, and wire transfer services, as well as online, mobile, text, and telephone banking services. The company has banking locations in Idaho Falls, Idaho; Ashton, Idaho; Pocatello, Idaho; St. Anthony, Idaho; Island Park, Idaho; Boise, Idaho; and Nampa, Idaho, as well as a mortgage origination office in Twin Falls, Idaho. The company was incorporated in 1985 and is based in Idaho Falls, Idaho.

Full BOID Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BOID vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BOID vs SCHDBOID vs JEPIBOID vs OBOID vs KOBOID vs MAINBOID vs JNJBOID vs MRKBOID vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.